Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
BACKGROUND
Lipoatrophy is prevalent on thymidine nucleoside reverse transcriptase inhibitors (tNRTIs). A pilot trial showed that uridine (NucleomaxX) increased limb fat.


METHODS
A5229 was a multicenter trial in which HIV-infected individuals with lipoatrophy on tNRTI regimens were randomized to NucleomaxX or placebo. Primary endpoint was change in limb fat from baseline to week 48. The study was powered to detect 400-g difference between arms at week 48. A stratified Wilcoxon rank-sum test was used to assess between-arm differences.


RESULTS
The 165 participants were 91% men, 62% white; median age 49 years, CD4 cell count 506 cells/μl, and limb fat 3037 g; 81% had HIV-1 RNA 50 copies/ml or less; 76% were on zidovudine (ZDV). Baseline characteristics were similar between groups. Only 59% completed 48 weeks of treatment; however, only three participants (one on uridine) discontinued due to toxicity (diarrhea). In intent to treat, there was no difference for changes in limb fat between treatments at week 24 or week 48. On as-treated analysis, uridine resulted in an increase in %limb fat vs. placebo (3.4 vs. -0.8%, P = 0.01) at week 24 but not at week 48 (1.8 vs. 3.8%, P = 0.93). Similar results were seen when limiting the analysis to patients with at least 80% adherence. The results were not related to severity of lipoatrophy or type of tNRTI. No changes were found in facial anthropometrics, fasting lipids, trunk fat, CD4 cell count, or HIV RNA.


CONCLUSIONS
We found a modest transient improvement in limb fat after 24 weeks of uridine. The lack of sustained efficacy at week 48 was not due to changes in adherence or reduction in sample size. Uridine was well tolerated and did not impair virologic control.
McComsey
Grace A
GA
Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, USA. gam9@case.edu
Walker
Ulrich A
UA
Budhathoki
Chakra B
CB
Su
Zhaohui
Z
Currier
Judith S
JS
Kosmiski
Lisa
L
Naini
Linda G
LG
Charles
Stéphannie
S
Medvik
Kathy
K
Aberg
Judith A
JA
D000328:Adult; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011788:Quality of Life; D014529:Uridine / Q000627:therapeutic use*; D019562:Viral Load; D016903:Drug Monitoring
D014529:Uridine
J Inherit Metab Dis. 1997 Aug;20(4):549-55
9266391
AIDS. 2004 Apr 30;18(7):1029-36
15096806
Antimicrob Agents Chemother. 1988 Jul;32(7):997-1001
3190201
Antivir Ther. 2003 Oct;8(5):463-70
14640394
Adv Exp Med Biol. 1979;122B:203-8
546145
Am J Pathol. 2008 Mar;172(3):681-90
18276780
Cancer Treat Rep. 1986 Jun;70(6):745-50
3731137
Antivir Ther. 2006;11(1):25-34
16518957
Blood. 1990 Dec 1;76(11):2210-5
2257294
J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):117-21
11832679
Hepatology. 2007 Jan;45(1):72-9
17187420
Cancer Res. 1984 Dec;44(12 Pt 1):5928-33
6498850
Clin Infect Dis. 2004 Jan 15;38(2):263-70
14699460
AIDS. 2003 Jun 13;17(9):1329-38
12799554
Eur J Clin Nutr. 2008 Aug;62(8):1031-7
17538545
Antivir Ther. 2003 Oct;8(5):485-7
14640397
AIDS. 2005 Apr 29;19(7):739-40
15821404
Antivir Ther. 2007;12(1):97-105
17503753
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):562-8
19561519
AIDS. 2006 Oct 24;20(16):2043-50
17053350
Mitochondrion. 2004 Jul;4(2-3):111-8
16120376